Pharmaceutical Executive-01-01-2018

Pharmaceutical Executive

Q&A: From Gleevec to CAR-T

January 12, 2018

Features

38

1

Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer-starting with Gleveec and continuing with last year’s approval of the first-ever CAR-T cell therapy-touching on the related broader issues such as pricing and value and new innovations in cancer science.

Prices and Competition to Shape the Year Ahead

January 11, 2018

Columns

38

1

States will continue to press for price controls, while FDA will tackle opioids and promote innovation.

CAR-T Concerns for Continued Success

January 09, 2018

From the Editor

38

1

The advent of immunocellular therapies marks a major milestone in pharma, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance,

Country Report: Switzerland

January 01, 2018

Special Sponsored Section

38

1

Three pivotal developments that occurred in 2017 illustrate the growing relevance and influence of the Swiss pharmaceutical and life sciences industry on the world stage. Companies in Switzerland are also playing innovative roles in reshaping the pharma value chain and contemporary paradigm of healthcare provision.

Pharmaceutical Executive, January 2018 Issue (PDF)

January 01, 2018

Issue PDF

38

1

Click the title above to open the Pharmaceutical Executive January 2018 issue in an interactive PDF format.